Hong Kong, being the gateway to China, provides a rich source of opportunities for overseas investors looking to capitalize on the growth of the Greater Bay Area (GBA). Meanwhile, for companies from China, Hong Kong is a bridge to connect with the West. Moreover, the new listing rules adopted by the Hong Kong Stock Exchange (HKEX) which allow pre-revenue biotech companies to be listed on the HKEX is a bold imperative step for the growth of the biotech sector in Hong Kong. Thus, we could not think of a better way to kick-start the Asian biotech revolution than by organizing BIOHK2022 convention in Hong Kong, the potential biotech epicentre of Asia. This is a golden opportunity to personally view the major GBA cities involved in the future of biotechnology by becoming a part of this historical event.